Notizie AIOM – anno XVII
Pembrolizumab Regimen Approved in China for Frontline Squamous NSCLC
November 26, 2019 - China’s National Medical Products Administration (NMPA) has approved the combination of pembrolizumab plus carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). The ...Leggi tutto
FDA Grants Priority Review to Pemigatinib for FGFR2+ Cholangiocarcinoma
November 27, 2019 - The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The designation is based ...Leggi tutto
2019 State of Lung Cancer Report Released
November 22, 2019 - More Americans than ever are surviving lung cancer. While the disease remains the leading cause of cancer deaths among both women and men, over the past decade, the survival rate has increased. A new report from the American Lung Association - the 2019 ...Leggi tutto
ASCO Guidelines on VTE Add New Oral Agents
November 19, 2019 - Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology (ASCO) now include the use of direct oral anticoagulants (DOACs) for patients with cancer as a preventive measure against VTE recurrence. To develop the ...Leggi tutto
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
November 21, 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to acalabrutinib for the treatment of adults with chronic ...Leggi tutto
FDA Accepts Application for Bevacizumab Biosimilar
November 19, 2019 - The FDA has accepted a biologics license application (BLA) for the proposed bevacizumab biosimilar SB8, according to Samsung Bioepis, the developer of the agent. Phase III findings for SB8 were presented at the 2019 ESMO Congress, in which the biosimilar ...Leggi tutto